Theriva Biologics Reports $13.1 Million Net Loss for Q2 2025 Amid Rising Expenses

Theriva Biologics, Inc. reported a net loss of $13.1 million, or $1.93 per share, for the three months ended June 30, 2025, compared to a net loss of $8.3 million, or $10.72 per share, for the same period in 2024. For the six months ended June 30, 2025, the company recorded a net loss of $17.4 million, or $3.64 per share, compared to a loss of $13.5 million, or $18.45 per share, in the prior year. The increase in losses is attributed primarily to a significant rise in general and administrative expenses, which surged to $11.2 million from $1.5 million year-over-year, largely due to a $9.2 million increase in the fair value of contingent consideration related to the successful completion of the VIRAGE Phase 2b clinical trial for its lead product candidate, VCN-01.

Total operating costs and expenses for the second quarter of 2025 reached $13.1 million, up from $8.5 million in the same quarter of 2024. Research and development expenses decreased to $2.0 million from $3.0 million, reflecting lower clinical trial costs associated with the VCN-01 program. The company’s accumulated deficit as of June 30, 2025, stood at approximately $352.4 million, indicating ongoing financial challenges as it continues to invest heavily in clinical development without generating revenue.

In terms of operational developments, Theriva Biologics has made significant strides in its oncology-focused pipeline, particularly with VCN-01, which has shown promising results in clinical trials for pancreatic cancer and retinoblastoma. The company has also been actively pursuing additional funding avenues, including a recent public offering that raised approximately $7.5 million. As of June 30, 2025, the company had cash and cash equivalents of $12.1 million, a slight increase from $11.6 million at the end of 2024, but still insufficient to cover anticipated operational costs beyond early 2026.

Looking ahead, Theriva Biologics is focused on advancing its clinical programs, particularly the VCN-01 trials, while exploring strategic partnerships and additional financing options to support its ongoing research and development efforts. The company has indicated that it will require further capital to continue its operations and complete future clinical trials, emphasizing the uncertainty surrounding its ability to secure necessary funding. The management has expressed that without additional financing, the company may need to limit its operations or cease certain development activities.